Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment

Diabetes and Vascular Disease Research

Volumn 11, Issue 1, 2014, Pages 34-40

  McGill, Janet B ^a   Barnett, Anthony H ^b   Lewin, Andrew J ^c   Patel, Sanjay ^d   Neubacher, Dietmar ^e   Von Eynatten, Maximilian ^e   Woerle, Hans Juergen ^e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c NATIONAL RESEARCH INSTITUTE   (United States)

^d BOEHRINGER INGELHEIM LTD   (United Kingdom)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

efficacy; Linagliptin; renal impairment; safety; sulphonylurea; type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; METFORMIN; SULFONYLUREA;

AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SEVERE RENAL IMPAIRMENT; VERY ELDERLY;

EFFICACY; LINAGLIPTIN; RENAL IMPAIRMENT; SAFETY; SULPHONYLUREA; TYPE 2 DIABETES;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MIDDLE AGED; PURINES; QUINAZOLINES; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SULFONYLUREA COMPOUNDS;

EID: 84890462520     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164113507068     Document Type: Article

References (31)

1. Huang ES, Liu JY, Moffet HH, et al. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011 ; 34: 1329-1336
2. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009 ; 31: 2608-2617
3. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009 ; 4: 1121-1127
4. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011 ; 86: 444-456
5. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis. 2007 ; 50: 865-879
6. Bailey CJ, Day C. Diabetes therapies in renal impairment. Br J Diabetes Vasc Dis. 2012 ; 12: 167-171
7. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012 ; 60: 850-886
8. Shrishrimal K, Hart P, Michota F. Managing diabetes in hemodialysis patients: observations and recommendations. Cleve Clin J Med. 2009 ; 76: 649-655
9. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 ; 35: 1364-1379
10. Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008 ; 25: 245-254
11. Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM. 2000 ; 93: 369-374
12. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002 ; 26: S18 - S24
13. Heise T, Graefe-Mody EU, Huttner S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009 ; 11: 786-794
14. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011 ; 13: 939-946
15. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011 ; 13: 258-267
16. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011 ; 13: 65-74
17. Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med. 2011 ; 28: 1352-1361
18. Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012 ; 380: 475-483
19. Gomis R, Owens DR, Taskinen MR, et al. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. Int J Clin Pract. 2012 ; 66: 731-740
20. Haak T, Meinicke T, Jones R, et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012 ; 14: 565-574
21. Barnett AH, Huisman H, Jones R, et al. Efficacy and safety of linagliptin in elderly patients (≥70 years) with type 2 diabetes mellitus. J Diabetes Investig. 2012 ; 3: 102
22. Lewin AJ, Arvay L, Liu D, et al. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2012 ; 34: 1909-1919.e15
23. McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013 ; 36: 237-244
24. Boehringer Ingelheim Pharmaceuticals, Inc. Tradjenta (linagliptin) 5 mg tablets, prescribing information (US), http://bidocs.boehringer-ingelheim.com/ BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/ Prescribing+Information/PIs/Tradjenta/Tradjenta.pdf (2012, accessed 21 June 2013).
25. Merck & Co., Inc (USA). Januvia (sitagliptin) tablets prescribing information (US), http://www.januvia.com/sitagliptin/januvia/hcp/januvia/index. jsp?WT.svl=1 (accessed 21 June 2013).
26. Takeda Pharmaceuticals USA, Inc. Nesina (alogliptin) tablets, prescribing information (US), http://www.takeda.us/products/ (accessed 21 June 2013).
27. Bristol-Myers Squibb Company. Onglyza (saxagliptin) tablets, prescribing information (US), http://packageinserts.bms.com/pi/pi-onglyza.pdf (accessed 21 June 2013).
28. Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009 ; 94: 1236-1243
29. Woerle HJ, Neubacher D, Patel S, et al. Safety and efficacy of linagliptin plus basal insulin combination therapy in a vulnerable population of elderly patients (age ≥70 years) with type 2 diabetes. Diabetologia. 2012 ; 55: S350
30. Melander A. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview. Diabetes. 2004 ; 53: S151 - S155
31. Gallwitz B, Rosenstock J, Emser A, et al. Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c < 7% with no hypoglycaemia and no weight gain over 2 years. Int J Clin Pract. 2013 ; 67: 317-321